A Neuro-Technological Intervention for Adolescents With GAD

Sponsor
National Healthcare Group, Singapore (Other)
Overall Status
Recruiting
CT.gov ID
NCT03813290
Collaborator
Duke-NUS Graduate Medical School (Other), Singapore General Hospital (Other), Nanyang Technological University (Other)
30
1
1
39.8
0.8

Study Details

Study Description

Brief Summary

This study aims to evaluate the safety and acceptability of a basic neuro-technological intervention in the treatment of adolescents with Generalised Anxiety Disorder (GAD). Our technology will deliver a mindfulness-based anxiety regulation intervention through a neuro- / bio-feedback-based virtual reality (VR) game interface that is driven by a novel algorithm.

Condition or Disease Intervention/Treatment Phase
  • Device: Neuro-technological Intervention
N/A

Detailed Description

This study is a single-arm open-label test of feasibility. The recruitment target is 30. Outpatient adolescents diagnosed with GAD will be recruited to undergo 8 x 30 minutes intervention sessions over 4 weeks. Participants who are enrolled will continue to receive treatment-as-usual prescribed by their treating psychiatrist, except for the use of psychotropics. This population is selected as they could elucidate whether our intervention can be beneficial as an early intervention program for GAD.

During the 8 bi-weekly intervention sessions, participants will don a head-mounted VR display set and a mobile EEG-biosensor. The hardwares are non-invasive.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
A Neuro-Technological Intervention for Adolescents With Generalised Anxiety Disorder (GAD): A Feasibility Trial
Actual Study Start Date :
Dec 8, 2020
Anticipated Primary Completion Date :
Apr 1, 2023
Anticipated Study Completion Date :
Apr 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Neuro-Technological Intervention

Participants will attend a total of 8 x 30 minutes intervention sessions (twice a week) for four consecutive weeks, starting within 1 week after baseline assessment. Participants will also be required to fill up some questionnaires at baseline and post-intervention visits.

Device: Neuro-technological Intervention
During the intervention sessions, participants will don a head-mounted VR display set and a mobile EEG-biosensor. Each session will begin with a brief audio-guided mindfulness practice, follow by a 15 minutes VR game. Game performances will be influenced by individual's level of anxiety arousal and ability to regulate it.
Other Names:
  • Brain Computer Interface
  • Mindfulness based Intervention
  • Outcome Measures

    Primary Outcome Measures

    1. Usability Questionnaire [Week 4]

      Usability questionnaire measures participants' experience with the neuro-technological intervention devices and software. Subscale with12 items asking about overall comfort and usability are included, with scale range of 1 to 4 (1 - very false for me, 2 - False, 3 - True, 4 - Very true for me). Subsequent 27-items subscale measures participants' experience with the software/virtual reality experience, with scale ranging from 1 to 7 (the lower the rating, the poorer the experience). Total score will be obtained from summing up the scores for each subscale. Higher score means better overall experience with the intervention.

    Secondary Outcome Measures

    1. Multidimensional Anxiety Scale for Children (Parent-reported); 2nd Edition [Week 0, 5]

      The MASC is a comprehensive, multi-rater assessment of anxiety dimensions in children and adolescents aged 8 to 19 years old. The MASC includes subscales scores for separation anxiety/phobias, GAD index, social anxiety, obsessions & compulsions, physical symptoms and harm avoidance. Raw scores from these subscales will be summed up to obtain the total score. Scale ranges from 0 to 3 (0 - Never, 1 - Rarely, 2 - Sometimes, 3 - Often). Higher raw scores indicate higher anxiety symptoms.

    2. Multidimensional Anxiety Scale for Children (Adolescent-reported); 2nd Edition [Week 0, 5]

      The MASC is a comprehensive, multi-rater assessment of anxiety dimensions in children and adolescents aged 8 to 19 years old. The MASC includes subscales scores for separation anxiety/phobias, GAD index, social anxiety, obsessions & compulsions, physical symptoms and harm avoidance. Raw scores from these subscales will be summed up to obtain the total score. Scale ranges from 0 to 3 (0 - Never, 1 - Rarely, 2 - Sometimes, 3 - Often). Higher raw scores indicate higher anxiety symptoms.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    13 Years to 18 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Between 13 to 18 years of age inclusive

    • Literate in English Language

    • Newly diagnosed with Generalised Anxiety Disorder: current episode, based on Computerised Diagnostic Interview Schedule for Children (C-DISC)

    • If on medication, dosage stable or unchanged for at least preceding 8 weeks

    • Has parental consent

    Exclusion Criteria:
    • Diagnosis (as defined by DSM-5) of: anxiety disorder induced by medication, substance, or another medical condition; obsessive compulsive disorder; bipolar disorder; any psychotic disorder (lifetime); intellectual disability (i.e. IQ<70); autism spectrum disorder; attention-deficit/hyperactivity disorder

    • History of substance or drug use disorder (as per DSM-5 criteria) within the last 3 months

    • Neurological disorders or insults (e.g. epilepsy, cerebrovascular accidents)

    • Metal in the cranium, skull defects, or skin lesions on scalp (e.g. cuts, abrasion, rash) at proposed electrode sites

    • Irregular heart rhythms or heart problems

    • Severe visual or hearing impairment

    • Prior experience with mindfulness-based therapy (e.g. mindfulness-based stress reduction [MBSR], mindfulness-based cognitive therapy [MBCT])

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Child Guidance Clinic Singapore Singapore 168937

    Sponsors and Collaborators

    • National Healthcare Group, Singapore
    • Duke-NUS Graduate Medical School
    • Singapore General Hospital
    • Nanyang Technological University

    Investigators

    • Principal Investigator: Lim Choon Guan, Institute of Mental Health, Singapore

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Lim Choon Guan, Senior Consultant and Deputy Chief, National Healthcare Group, Singapore
    ClinicalTrials.gov Identifier:
    NCT03813290
    Other Study ID Numbers:
    • DSRB A/2018/00693
    First Posted:
    Jan 23, 2019
    Last Update Posted:
    Apr 6, 2022
    Last Verified:
    Apr 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Lim Choon Guan, Senior Consultant and Deputy Chief, National Healthcare Group, Singapore
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 6, 2022